GSK Appoints Dr Gavin Screaton to Board, Replacing Dr Jesse Goodman

Portfolio - People | Feb 21, 2025 | GSK PLC

GSK plc has announced that Dr. Gavin Screaton will join its Board as an Independent Non-Executive Director effective 1 May 2025. Dr. Screaton succeeds Dr. Jesse Goodman, who will retire after nine years of service. Dr. Screaton brings significant expertise in immunology and infectious diseases, crucial areas for GSK, given his current role at the University of Oxford and his involvement in other scientific and public health positions. His appointment, facilitated by an extensive search conducted by the Nominations & Corporate Governance Committee, will see him join the Board's Science Committee and Corporate Responsibility Committee. His remuneration includes standard fees for a Non-Executive Director, additional compensation for scientific expertise, and he will be expected to build a share ownership in GSK. The Board change reflects GSK’s ongoing commitment to integrating scientific and industry expertise at the governance level.

Sectors

Biopharmaceutical
Healthcare

Geography

United Kingdom – GSK is headquartered in the UK, and Dr. Gavin Screaton's current academic and professional involvements are also based in the UK.

Industry

Biopharmaceutical – GSK operates in the biopharmaceutical industry, focusing on uniting science, technology, and talent to combat diseases, which aligns with their recent board appointment.
Healthcare – The appointment of Dr. Gavin Screaton, an expert in immunology and infectious diseases, underscores GSK’s involvement in healthcare, particularly in research and public health sectors.

Financials

122,258 – Standard basic fee per annum for a Non-Executive Director at GSK, including travel allowance.
30,000 – Additional annual fee for scientific and medical expertise for a Non-Executive Director at GSK.

Participants

Name	Role	Type	Description
GSK plc	Target Company	Company	A global biopharmaceutical company focusing on advancing healthcare solutions.
Dr. Gavin Screaton	Incoming Non-Executive Director	Person	A leading expert in immunology from the University of Oxford, joining GSK's Board.
Dr. Jesse Goodman	Retiring Non-Executive Director	Person	Former FDA Chief Scientist stepping down from the GSK Board after nine years.
Sir Jonathan Symonds	Chair of GSK	Person	The Chair of GSK's Board, overseeing the recent Board transitions.
Nominations & Corporate Governance Committee	Search Committee	Company	Responsible for conducting the search and selection process for the Board appointment.